SAN FRANCISCO / Jun 29, 2023 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its 2023 State of Telemedicine Report, revealing that nearly 88% of U.S. physicians surveyed believe telemedicine has increased patient access to health care, particularly among populations that may have faced barriers to care previously. The study also found a number of physician time-management benefits, such as improved schedule management, productivity, and autonomy and work-life balance.
As part of the study, Doximity analyzed the adoption of its telemedicine tools across its physician users and surveyed both patients and physicians about their experiences with telemedicine.* Physicians reported several patient access benefits, with the majority reporting reduced patient no-show rates and equivalent or better adherence to treatment plans. Patients with telemedicine experience in the past year also reported greater access to health care services and higher satisfaction with their care.
“Telemedicine helps doctors provide care to a wide range of patients, including many who need increased access to care,” said Nate Gross, MD, co-founder and chief strategy officer at Doximity. “The results of our study suggest a permanent role for telemedicine, with benefits to productivity, work-life balance and equitable access.”
Physician adoption highlights:
Patient adoption highlights:
For more information, view Doximity’s 2023 State of Telemedicine Report.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.
*Doximity surveyed over 1,200 U.S. physicians across nine specialties and 2,400 patients.
Last Trade: | US$49.92 |
Daily Change: | 0.02 0.04 |
Daily Volume: | 139,751 |
Market Cap: | US$6.400B |
November 07, 2024 October 31, 2024 August 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB